[Treatment of thalassemia and sickle cell anemia in children].
Girot
R
R
D000755:Anemia, Sickle Cell / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D000986:Antisickling Agents / Q000627:therapeutic use; D001803:Blood Transfusion / Q000379:methods; D002648:Child; D005602:France; D006454:Hemoglobins / Q000032:analysis; D006486:Hemosiderosis / Q000209:etiology / Q000517:prevention & control; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D017053:Infection Control; D007502:Iron Chelating Agents / Q000627:therapeutic use; D009154:Mutation / Q000235:genetics; D010102:Oxygen Inhalation Therapy / Q000379:methods; D010353:Patient Education as Topic; D018579:Patient Selection; D010372:Pediatrics / Q000379:methods*; D011379:Prognosis; D013156:Splenectomy; D013789:Thalassemia / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D065227:Transfusion Reaction; D014665:Vasodilator Agents / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000986:Antisickling Agents; D006454:Hemoglobins; D007502:Iron Chelating Agents; D014665:Vasodilator Agents; D014815:Vitamins